A group of people with ALS taking part in MIROCALS have generously agreed to also participate in an additional study at Brighton and Sussex Medical School.

The ANNALS-QuICT (Analysing Neuroinflammation in Neurodegeneration in Amyotrophic Lateral Sclerosis) study uses Magnetic Resonance Imaging (MRI) scanning to look for changes occurring in the brain over time. Up to 50 participants are being scanned on two separate occasions: a ‘baseline’ scan before being randomised to the treatment or placebo; and a ‘follow-up’ scan 4-6 months later. An additional 25 volunteers who do not have ALS are being recruited as controls.

“We are using a range of novel MRI approaches which will provide information on the architecture of the neurons, their density, the surrounding insulating material and the amount of communication that occur between brain regions.” explains Dr Andrew Barritt, the Clinical Research Fellow running the study.

“Taking part in this additional research has required the participants to devote more of their time and sometimes travel significant distances. We’re immensely grateful for their dedication and support. We hope that these studies will help us to further our understanding of the changes that occur over the course of this terrible disease, aiding the development and testing of future treatments.


End of trial recruitment phase this autumn

The MIROCALS (Modifying Immune Response and Outcomes in ALS) Clinical Trial is still on-going, with recruitment continuing until the end of September 2019.

Read more

Charities and Patient Associations rally around MIROCALS to show their support

Clinical trials are expensive to run and with several more neurology clinics taking part, ...

Read more

Will Brexit impact on MIROCALS?

As with everything else affected by Brexit, there are probably more questions than answers!

Read more

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 633413.